Join
Live feed
·
NEWSReleasevia Quantisnow
Enlivex Ltd. logo

Enlivex Announces Dosing Of First Two Patients In Its Randomized, Controlled Phase I/II Trial Evaluating Allocetra In Patients With Knee Osteoarthritis

ByQuantisnow·Wall Street's wire, on your screen.
ENLV· Enlivex Ltd.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ENLV (Enlivex Ltd.) and more on Quantisnow.

Enlivex Announces Dosing Of First Two Patients In Its Randomized, Controlled Phase I/II Trial Evaluating Allocetra In Patients With Knee Osteoarthritis | Quantisnow